Lexapro (Escitalopram) Onsite Taper

No. You arrive on your current prescribed escitalopram dose and the taper is done onsite under continuous cardiac telemetry, bridged with sub-psychoactive full-spectrum iboga total alkaloid at 50–150 mg BID. MindScape does not ask you to attempt a solo washout at home before treatment. A small number of other medications — MAOIs, lithium, tricyclic antidepressants, tramadol and certain QT-prolonging cardiac medications — do still need to be cleared before you arrive, so our medical team reviews your full medication list in advance.

Typically 10–18 days onsite. That range is driven by escitalopram's intermediate half-life — ≈ 27–32 hours — and your baseline dose, usually 5–20 mg/day. Reductions are hyperbolic rather than linear, so the schedule follows how you actually respond instead of running to a fixed calendar.

The escitalopram discontinuation profile covers: Brain zaps (electric-shock paresthesias); Dizziness, vertigo, gait instability; Anxiety rebound and panic surges; Irritability and emotional lability; Insomnia and vivid dreaming. The onsite protocol bridges the taper with sub-psychoactive iboga total alkaloid (50–150 mg BID) to cover the receptor-occupancy gap as your dose comes down, with symptom-driven support and continuous monitoring throughout.

The 5 mg → 2.5 mg → 0 step is the steepest receptor-occupancy drop in the entire taper curve. Most patients tapering escitalopram at home reinstate within 2 weeks because the symptoms are misattributed to underlying depression. Compounded liquid escitalopram is rarely available outside specialty pharmacies.

Yes. Baseline cardiac, hepatic, electrolyte, and pharmacogenomic workup. Hyperbolic taper using compounded liquid escitalopram: 50% step reductions every 5–7 days. Iboga TA bridge 50–150 mg BID through the steepest receptor-occupancy drop. Continuous telemetry; symptom-driven adjuncts (ondansetron, hydroxyzine, magnesium).

A flood dose of ibogaine HCl is only administered once escitalopram has been reduced to a protocol-defined safe threshold and your cardiac screening is still within limits — eligibility is confirmed at that point rather than promised in advance. Ibogaine is an investigational compound, is not approved by the FDA, and results vary between patients. If your medication picture or your screening makes treatment unsafe, we will tell you honestly.